Our findings showcase the advantage of using blood cells and the expression of genes associated with the DNA repair for human radiation biodosimetry, and furthermore that these genes have the ability to discriminate between radiation dose and inflammation stress. In a survey of 40 DNA repair genes in the human peripheral blood cells
ex vivo radiation model (
Table S1), twelve genes showed more than two fold changes in transcript levels at 24 hours after 2 Gy exposures. These included the cell cycle regulators (
CDKN1A,
GADD45a, PCNA and
CCNG1), apoptosis regulators (
BAX,
BBC3 and
FDXR) and genes involved in specific DNA repair functions (
XPC, DDB2, LIGI, POLH and
RAD51). We compared the responses to radiation and inflammation stress to develop a panel of 8 genes that we validated using publicly available expression datasets for (1) an independent group of donors in a blood
ex vivo model, and (2) a second independent group of patients who provided blood samples before and after whole body radiation (
[10],
[12],
[35], ). Our findings support the strength of using DNA repair related genes to detect radiation exposure in the context of inflammation stress, which may become helpful for discriminating between worried-well, those exposed to medically significant doses of ionizing radiation and those experiencing inflammation stress (). By including protein expression markers we developed a 9-gene panel (8 transcripts and one protein marker) that correctly discriminated irradiated from unirradiated blood samples independent of the presence or absence of inflammation stress (), with a ~90% 4-group classification accuracy ().
The DNA repair-associated genes we surveyed are regulated by TP53 signaling
[37]. The TP53 tumor suppressor protein is central to cell signaling networks following cellular stressors, including DNA damage such as that caused by ionizing radiation. TP53 modulates the main DNA repair processes in eukaryotic cells (base excision repair (BER), nucleotide excision repair (NER), non-homologous end-joining (NHEJ) and homologous recombination (HR) along with direct roles in induction of DNA damage-induced cell cycle arrest and apoptosis. TP53 is activated after DNA damage through phosphorylation to function as a transcriptional regulator inducing expression of a number of downstream target genes that directly control cellular outcomes
[38]. Activators of TP53 include CHK2, a serine/threonine kinase that, upon activation directly by ATM phosphorylation (e.g., threonine-68) or indirectly by other protein kinases (e.g., DNA-PKcs), acts as both a downstream signal transducer of DNA damage and an effector for DNA repair, checkpoint control and apoptosis
[39]. In our study we did not observe changes in transcript expression of
CHK2 following irradiation, consistent with the role of CHK2 as an upstream mediator of TP53 rather than a downstream target, however, an increase in phosphorylated CHK2 protein was observed. Phosphorylation of TP53 at serine-20 by CHK2 prevents MDM2-mediated TP53 degradation. This enhancement of TP53 stability allows for the continuance of downstream DNA damage response pathways including apoptosis, of which BAX is an effector
[40]. CHK2, a direct substrate of ATM, is an earlier DNA damage response protein than BAX. Hirao et al.
[41] observed by Western blot that CHK2 levels in both sham- and 5 Gy irradiated wild-type mouse thymocytes precede BAX up until 6 h post-irradiation, which is consistent with our protein ELISA results post-irradiation.
Our radiation-response results in the
ex vivo blood model are consistent with previous human studies
[6],
[8],
[10],
[23]–
[25],
[42] with the exception of
RAD51, which showed a decrease in expression in our study
[43]. A recent study in mice of radiation effects on gene expression showed significant increases in expression of
CDKN1A, BBC3 and
GADD45a at 24 hrs after 2 Gy whole body irradiation
[42]. However, in that study
DDB2 was downregulated and no significant changes were observed for
FDXR or
XPC, which is inconsistent with our results and those of others in humans irradiated
ex vivo
[10]. Expression of
GADD45a, LIG1 and
XPC were decreased at 24 hours after 6 Gy IR in mice, whereas we observed increased expression at 24 hrs after 2 Gy in our
ex vivo human blood culture model consistent with published human
ex vivo and
in vivo literature
[7],
[12],
[30]. Also, our use of a 2 Gy exposure (rather than 6 Gy used in a prior mouse study
[30]) is more relevant for radiation biodosimetry because individuals having a radiation exposure dosage of less than 2 Gy require no immediate treatment as opposed to those having a dosage higher than 2 Gy. The inherent differences between murine and human assays emphasize the importance of using human model systems to validate biomarkers for human radiation biodosimetry. Our study investigates the blood of unrelated people and we confirm our findings in a separate independent group of unrelated people, suggesting that interindividual variation in the transcript response is not a major factor for the genes in our panel.
Understanding the effects of confounding factors, such as inflammation stress, on radiation-responsive biomarkers is important for assessing their utility in radiation biodosimetry in practical human exposure scenarios
[1],
[2], . Of the 8 radiation-responsive genes in our study, only three (
CDKN1A, FDXR and
BBC3) were confounded by LPS-induced inflammation stress.
CDKN1A is a canonical marker of DNA damage response and has been proposed as a biomarker of radiation exposure
[7],
[42]. While cigarette smoking did not confound the radiation response of
CDKN1A
[29], our study shows that inflammatory stress induced
CDKN1A transcript levels in the absence of radiation exposure. Our finding seriously undermines the promise of
CDKN1A as a predictive tool for radiation exposure in individuals suffering simultaneous inflammatory stress. Studies in the murine central nervous system also identified
CDKN1A as an inflammatory response gene
[44] and LPS exposure upregulated
CDKN1A transcripts in mice
[30]. LPS-induced and the radiation-induced
CDKN1A responses were indistinguishable in our human blood model, while in the mouse the upregulation of
CDKN1A at 24 hours after LPS injection did not mask the ability to detect a radiation response
[30]. This difference in murine vs human responses might be attributed to the differences in LPS dosage (50 ng/ml in our study vs. 0.3 mg/kg which equals 7.2 µg per mouse), LPS bioavailability and species differences in response.
We have made the new observation that LPS co-treatment confounds the transcript response of
FDXR and
BBC3, also compromising their utility as radiation biodosimeters. The pro-apoptotic gene,
BBC3, is responsible for induction of apoptosis pathways following DNA damage. Whole blood cultured in the presence of LPS repressed the expression of
BBC3 ~2.5-fold. Co-treatment with LPS and radiation diminished
BBC3 transcripts compared to either LPS alone or radiation alone. Consistent with our finding, LPS suppressed apoptosis in human blood monocytes
[45], but some studies found opposite responses
[33]. The transcription of
BBC3 is regulated by a complex combination of pro-apoptotic and pro-survival mechanisms
[46], suggesting that LPS may suppress
BBC3 transcription in blood cultures through activation of pro-survival signals. In contrast to our findings, Tucker and colleagues observed a marginal confounding effect of LPS treatment on the radiation response of
BBC3 in mice
[30], again emphasizing the importance of validating biomarker panels in a human model.
The increases in protein levels of phosphorylated CHK2 after radiation-alone exposures were fully suppressed in the presence of LPS, also undermining it as a useful protein biomarker for radiation response in the context of inflammation stress. CHK2 protein is phosphorylated in response to DNA damage which activates the protein
[13],
[36]. While we demonstrate that LPS co-treatment fully abrogates this radiation-induced CHK2 phosphorylation process, the underlying mechanisms for this confounding effect remain unclear.
The LPS-modified
CDKN1A, FDXR and
BBC3 transcript levels were remarkably uniform among donors, even though the secretions of IL-6 and TNF-α two genes well-known to be induced by LPS, were more variable (
Figure S4). The levels of LPS-induced IL-6 and TNF-α were highly correlated (R
2
=

0.8;
Figure S6). Among 4 of the donors, IL-6 and TNF-α levels in the first blood draw were nearly identical to those in the second blood draw, 1 month later. These findings point to the hypothesis that the induction of inflammatory response genes IL-6 and TNF-α depend on genetic background, while the inductions of
CDKN1A and
BBC3 are more ‘switch-like’. This would predict that other confounding stimuli might also affect
CDKN1A and
BBC3 expression.
Our research has identified a small panel of DNA repair-related biomarkers that distinguish among human blood samples from four radiation exposure scenarios: no radiation exposure, 2 Gy radiation exposure only, inflammation stress without radiation exposure, and combined 2 Gy exposure plus inflammation stress. Independent validation for dose and time response and with
in vivo total body irradiated samples further supports the utility of these biomarkers for clinical applications, accident scenarios and other situations involving potential radiation exposure. Future studies will be needed to evaluate our panel for effects of gender, age, and inter-individual variations, to examine the influence of differential radiation cytotoxicities of the white cell subtypes on expression biodosimetry
[47], and to investigate the radiation specificity of our panel using other inflammation, chemical, and physical stressors that are relevant for human radiation biodosimetry applications in various hypothetical exposure scenarios.